We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Diagnostic Imaging Solutions for Alzheimer’s at RSNA 2019
Product News

Diagnostic Imaging Solutions for Alzheimer’s at RSNA 2019

Diagnostic Imaging Solutions for Alzheimer’s at RSNA 2019
Product News

Diagnostic Imaging Solutions for Alzheimer’s at RSNA 2019


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Diagnostic Imaging Solutions for Alzheimer’s at RSNA 2019"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CorTechs Labs, a quantitative neuroimaging software company, has announced that they will be exhibiting at RSNA 2019, which is taking place from December 1-6, 2019. In addition to technical exhibits on both the main floor and AI Showcase, the company will present their findings from a recent study titled: “Determining Brain Age Using Machine Learning Combined with Automated Brain Segmentation and PET Imaging in Normal, Alzheimer's Disease and Mild Cognitive Impairment Subjects.” The company has a number of other presentations throughout the conference and will be at booth numbers 4055 in South Hall, Level 3 and 10514F in the AI Showcase, Level 1.

CorTechs Labs recently developed a machine learning-based age-prediction model for metabolic and volumetric changes of normal brain structures and evaluated this model on imaging data from patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), as well as control subjects. The company will be presenting its findings at the conference around the understanding that determining brain aging may be critical to identify potential biomarkers in neurodegenerative diseases, such as Alzheimer’s disease.

“Our goal is to supply innovative technology that enables physicians to provide excellent care with a very high degree of accuracy,” said Chris Airriess, chief executive officer of CorTechs Labs. “As the diagnostic neuroimaging market grows and the technology advances, the research insights such as those we are presenting at RSNA will continue to improve the early, accurate diagnosis of Alzheimer’s disease as well as other neurological disorders.”
CorTechs Labs will have the following three different presentations at RSNA 2019:

  • Wednesday 3:30-3:50 p.m.: AI-Powered Diagnostic Decision Support Using Volumetric Biomarkers and Non-Imaging Patient Data (Innovation Theater Presentation). Presented by CEO Chris N Airriess, PhD and Director of Science and Engineering, Sebastian Magda, PhD

           Session: IN08D, in South Hall Level 3

  • Thursday 12:15-12:45 p.m.: Determining Brain Age Using Machine Learning Combined with Automated Brain Segmentation and PET Imaging In Normal, Alzheimer's Disease and Mild Cognitive Impairment Subjects (Poster Discussion). Presented by Weidong Luo, PhD.

           Session: AI262-SD-THA1, in the AI Community, Learning Center

  • Thursday 12:30-12:50 p.m.: AI-Powered Volumetrics to Improve Radiologist Efficiency and Accuracy (AI Theater Presentation). Presented by Clinical Specialist, Micki Maes.

           Session: AI55, in AI Showcase, North Building, Level 1


CorTechs Labs have also recently announced the appointment of Paul Mirabella, a healthcare and diagnostic imaging industry veteran, to the company’s board of directors. “I am extremely passionate about working with innovative technology companies to try to improve the outcomes and efficiency of the health care system,” said Mirabella. “I look forward to building upon the CorTechs Labs current momentum to deploy leading-edge technology providing medical professionals with deeper insights into the diagnosis of neurodegenerative diseases and, most importantly, elevates patient care.”

Advertisement